EC marketing authorisation granted to Pfizer’s HYMPAVZI for haemophilia
The EC has granted marketing authorisation for Pfizer's anti-tissue factor pathway inhibitor (anti-TFPI), HYMPAVZI to treat haemophilia.
The EC has granted marketing authorisation for Pfizer's anti-tissue factor pathway inhibitor (anti-TFPI), HYMPAVZI to treat haemophilia.
What's Your Reaction?
